Ovarian Cancer Canada

Western Regional Blog – BC, YK, AB, NWT and Nunavut

Ascites Predicts Bevacizumab Benefit in Advanced Ovarian Cancer

“Malignant ascites independently predicts poor prognosis among women with newly diagnosed advanced ovarian cancer, and thus may predict the likelihood of deriving long-term benefit from bevacizumab treatment…”

April 22, 2014

EMA recommends approval of new treatment for platinum-resistant ovarian cancer together with companion diagnostic

Vynfinit gains European approval for treatment of platinum-resistant ovarian cancer.

April 22, 2014

Study discovers genetic cause of rare type of ovarian cancer

Causative mutation found for rare form of ovarian cancer affecting young women A rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (or SCCOHT)

April 22, 2014

Bevacizumab Plus Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer

TAKE-HOME MESSAGE  This randomized trial enrolled 361 platinum-resistant ovarian cancer patients who received single-agent chemotherapy

April 22, 2014

Oophorectomy Reduces Cancer Risk and Mortality in BRCA1 and BRCA2 Carriers

Full article: J Clin Oncol. 2014 Feb 24. [Epub ahead of print].  An epidemiologic study of 5783 women with BRCA1 or BRCA2 mutations demonstrated that preventive bilateral oophorectomy reduced the … Continue reading

April 1, 2014

Increased Risk for Ovarian Cancer and Borderline Ovarian Tumours in Subfertile Women With Endometriosis

Is There a Link Between Endometriosis and Ovarian Cancer?  Peter Kovacs, MD, PhD Buis CC, van Leeuwen FE, Mooij TM, Burger CW; OMEGA Project Group / Hum Reprod. 2013;28:3358-3369 http://www.medscape.com/viewarticle/822537?src=wnl_edit_tpal&uac=185065HV Continue reading

April 1, 2014

Chemotherapy Hypersensitivity Reactions in Ovarian Cancer

“Drug desensitization has emerged as a safe and effective way of reintroducing a chemotherapeutic agent or monoclonal antibody responsible for an HSR (hypersensitivity reaction) in a patient who is expected … Continue reading

April 1, 2014

For Women’s Cancers, Where You’re Treated Matters

Patients at highest-volume hospitals live more than a year longer on average, study finds  By Robert Preidt http://www.nlm.nih.gov/medlineplus/news/fullstory_145272.html  MONDAY, March 24, 2014 (HealthDay News) — Where you’re treated for ovarian … Continue reading

April 1, 2014

Veliparib Active in BRCA-Positive Ovarian Cancer

“In a phase 2 study of 50 women with BRCA gene mutations, treatment with veliparib resulted in a 26% objective response rate, according to RECIST criteria. Two of these women … Continue reading

April 1, 2014

Complementary and Alternative Therapies

CAMEO

Research in BC

The Injustices of Ovarian Cancer

Ovarian Cancer Canada